Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Generic Share at 55% in September 2014: MHLW
February 19, 2015
- Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
- Add Risk of Interstitial Pneumonia to Eliquis Package Insert: MHLW
February 18, 2015
- Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
- LDP Pharma Policy Study Group on Alert for 3 Consecutive Years of Drug Price Cuts
February 17, 2015
- MHLW Approves 309 Generic Products Ahead of June Listing; 32 Companies Obtain Approval for Plavix Generics Including AGs
February 17, 2015
- Panel Approves 43 More Diseases as Designated Intractable Diseases
February 17, 2015
- Gilead Told to Improve Biz Practice in Japan over Delayed ADR Reporting
February 16, 2015
- Health Minister to Kick Off Roundtable for Healthcare Policy for 2035 This Month
February 16, 2015
- PAFSC’s Second Committee to Discuss Celgene’s Multiple Myeloma Treatment Pomalidomide on Feb. 26
February 13, 2015
- PMDA Plans Manufacturing Inspections for 2 Regenerative Medicine Products This Year
February 12, 2015
- MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
- Health Minister Says to Mull Revising Generic Share Target
February 10, 2015
- National Cancer Center Announces Guidelines for Clinical Trial Monitoring and Auditing
February 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 26 - Feb. 8
February 9, 2015
- PAFSC 1st Committee to Discuss Actelion’s PAH Treatment on Feb. 20
February 9, 2015
- Panel OKs Intractable Disease Designation of Muscular Dystrophy
February 6, 2015
- NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
- MHLW Plans Business Suspension Order for Novartis
February 5, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…